Document is current
Any future updates will be listed below
-
Authors
Schmidt, Andreas
Bernhardt, Christiane
Bürkle, Dieter
Fries, Stefan
Hannig, Carla V.
Jentsch-Ullrich, Kathleen
Josting, Andreas
Kreher, Stephan
Reiser, Marcel
Steinmetz, Hans Tilman
Tesch, Hans
Terner, Stephanie
Schulte, Alexander
Crodel, Carl C.
Palandri, Francesca
Heidel, Florian H. https://orcid.org/0000-0003-2438-1955
-
Funding
Funding for this research was provided by:
Novartis Pharma (MF-Retro2, MF-Retro2, MF-Retro2, MF-Retro2, MF-Retro2, MF-Retro2, MF-Retro2, MF-Retro2, MF-Retro2, MF-Retro2, MF-Retro2, MF-Retro2)
Universitätsmedizin Greifswald
- License Information
-
More Information
Article History
Received: 17 February 2023
Accepted: 24 February 2023
First Online: 8 March 2023
Declarations
:
: Study conception and data collection was supported by a Grant (MFRetro2) from Novartis Inc., ST and AS are employed by Novartis Pharma GmbH. FHH contributed as consultant, AdBoard member and invited speaker for Novartis, Bristol Myers Squibb, Cell Therapeutics Inc (CTI-Biopharma), AOP-Orphan and Janssen and has received research funding from Novartis, Bristol Myers Squibb and Cell Therapeutics Inc (CTI-Biopharma).
: The chart review did not involve the collection of any personally identifiable data, and its findings were presented as averaged datasets for each center. The institutional review board examined and approved the questionnaires and study materials.
